Tenor Capital Management’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Tenor Capital Management’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.01K	Hold	50,000	–	–	﹤0.01%	492
2025 Q4	$1.3K	Hold	50,000	–	–	﹤0.01%	424
2025 Q3	$1.76K	Hold	50,000	–	–	﹤0.01%	383
2025 Q2	$2.04K	Hold	50,000	–	–	﹤0.01%	342
2025 Q1	$3.83K	Hold	50,000	–	–	﹤0.01%	267
2024 Q4	$1.7K	Hold	50,000	–	–	﹤0.01%	275
2024 Q3	$1.58K	Buy	+50,000	New	+$2.9K	﹤0.01%	270

Other funds holding SLXNW

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.39% 1-Year Est. Return

Tenor Capital Management's SLXNW Position: Q1 2026 in Review

Tenor Capital Management held its Silexion Therapeutics Warrant (SLXNW) position steady in Q1 2026 at 50,000 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #492.

Tenor Capital Management first reported a position in SLXNW in Q3 2024 and has held it in 7 quarters since. The position peaked at $3.83K in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q1 2026.

Tenor Capital Management held 50,000 shares of Silexion Therapeutics Warrant worth $1.01K as of Q1 2026.
Tenor Capital Management left its Silexion Therapeutics Warrant share count unchanged in Q1 2026.
Silexion Therapeutics Warrant made up ﹤0.01% of Tenor Capital Management's portfolio in Q1 2026, its #492 holding.
Tenor Capital Management first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 7 quarters since.
Tenor Capital Management's Silexion Therapeutics Warrant position peaked at $3.83K in Q1 2025.
19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q1 2026.

Based on Tenor Capital Management's 13F filing for Q1 2026, filed 15 May 2026.